文献速递血管炎

意大利北部大血管巨细胞动脉炎的复发与长期缓解:长期随访研究

Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study.
PubMed 文献 · Semin Arthritis Rheum · 2020-05-20

该研究纳入意大利Reggio Emilia医院87例大血管巨细胞动脉炎(LV-GCA)连续患者并随访至少2年,评估复发与长期缓解的特征及预测因素。37例(42.5%)出现复发,35/84例(41.6%)达到长期缓解;多变量模型显示发热≥38°C与累积泼尼松剂量增加复发风险,主动脉弓受累与长期缓解降低复发风险。

要点

  • LV-GCA患者中约四成出现复发,多数复发发生于泼尼松≤10 mg/日时。
  • 发热≥38°C与累积泼尼松剂量是复发的独立危险因素。
  • 复发与累积泼尼松剂量与长期缓解呈负相关。

核心结论

  • 在LV-GCA队列中识别出复发病程与长期缓解的预测因素,二者各见于约半数患者。

研究设计与样本

  • 意大利Reggio Emilia医院风湿科87例连续LV-GCA患者随访至少2年,并与34例活检证实无大血管炎(LVV)的GCA患者比较。

主要发现

  • 复发时多数泼尼松剂量≤10 mg/日(74.5%),最常见表现为风湿性多肌痛(41.2%)与影像学LVV加重(39.2%)。
  • 复发患者累积泼尼松剂量更高(p<0.0001)、治疗时间更长(p<0.0001),诊断时发热≥38°C(p=0.03)与视觉表现(p=0.03)更常见,长期缓解更少(p=0.002)。
  • 多变量模型中发热≥38°C(HR 2.30,95%CI:1.11-4.78)与累积泼尼松剂量(HR 1.18,95%CI:1.08-1.30)增加复发风险,诊断时影像学主动脉弓受累(HR 0.26,95%CI:0.11-0.59)与长期缓解(HR 0.27,95%CI:0.11-0.65)降低复发风险。
  • 35/84例(41.6%)达到长期缓解,其风湿性多肌痛(p=0.04)与复发(p=0.002)更少、累积泼尼松剂量更低(p<0.001);多变量模型中复发(HR 0.21,95%CI:0.07-0.62)与累积泼尼松剂量(HR 0.85,95%CI:0.77-0.95)与长期缓解显著负相关。

关键数值与推荐

  • 长期缓解:35/84例(41.6%)达到长期缓解。

临床怎么用

  • 对LV-GCA患者应关注诊断时发热≥38°C、视觉表现及累积泼尼松剂量等复发高危因素并加强随访。
  • 诊断时影像学主动脉弓受累可能与较低复发风险及较高长期缓解相关,可用于风险分层。

局限性

  • 单中心队列研究,样本量有限(87例LV-GCA),结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate characteristics and predictors of relapses and long-term remission in an Italian cohort of patients with large-vessel (LV) giant cell arteritis (GCA). METHODS: We evaluated 87 consecutive patients with LV-GCA followed up at the Rheumatology Unit of Reggio Emilia Hospital (Italy) for at least 2 years. Patients with relapses and long-term remission were compared to those without. A group of 34 patients with biopsy proven GCA without LV vasculitis (LVV) at diagnosis was considered for comparison. PATIENTS: 37 patients (42.5%) experienced one or more relapses. Nineteen (37.2%) of the 51 relapses were experienced during the first year after diagnosis. The majority of relapses occurred with doses of prednisone (PDN) ≤ 10 mg/day (74.5%). Polymyalgia rheumatica (PMR) (41.2%) and worsening at imaging of LVV (39.2%) were the most frequently observed relapsing manifestations. The total cumulative prednisone dose was significantly higher (p < 0.0001) and the total duration of PDN treatment longer (p < 0.0001) in relapsing patients compared to those without relapses. Relapsing patients had at diagnosis more frequently fever ≥ 38°C (p = 0.03) and visual manifestations (p = 0.03), and less frequently long-term remission (p = 0.002). In the multivariate model fever ≥ 38°C (HR 2.30, 95%CI:1.11-4.78) and total cumulative PDN dose (HR 1.18, 95%CI: 1.08-1.30) were significantly associated with an increased risk of relapses, while aortic arch involvement at imaging at diagnosis (HR 0.26, 95%CI: 0.11-0.59) and long-term remission (HR 0.27, 95%CI: 0.11-0.65) with a reduced risk. 35/84 patients (41.6%) experienced long-term remission. PMR and disease relapses were less frequently observed (p = 0.04 and p = 0.002, respectively), and the total cumulative prednisone dose was lower (p < 0.001) in patients with long-term remission compared to those without. In the multivariate model the presence of relapses (HR 0.21, 95%CI: 0.07-0.62) and the total cumulative PDN dose (HR 0.85, 95%CI: 0.77-0.95) were significantly negatively associated with long-term remission. CONCLUSION: In our cohort of patients with LV GCA we identified predictors of a relapsing course and long-term remission, which were observed in around half of the patients.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Muratore F, Boiardi L, Restuccia G, et al. Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study. Semin Arthritis Rheum. 2020. PMID: 32446023. doi:10.1016/j.semarthrit.2020.04.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。